<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Int AIDS Soc</journal-id><journal-id journal-id-type="iso-abbrev">J Int AIDS Soc</journal-id><journal-id journal-id-type="publisher-id">JIAS</journal-id><journal-title-group><journal-title>Journal of the International AIDS Society</journal-title></journal-title-group><issn pub-type="epub">1758-2652</issn><publisher><publisher-name>International AIDS Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25397520</article-id><article-id pub-id-type="pmc">4225274</article-id><article-id pub-id-type="publisher-id">19776</article-id><article-id pub-id-type="doi">10.7448/IAS.17.4.19776</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Sessions &#x02013; Abstract P244</subject></subj-group></article-categories><title-group><article-title>Long-term effect of a four-drugs induction regimen for patients with high baseline viral load</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Maggiolo</surname><given-names>Franco</given-names></name><xref ref-type="aff" rid="AF0001_19776">1</xref></contrib><contrib contrib-type="author"><name><surname>Masini</surname><given-names>Giulia</given-names></name><xref ref-type="aff" rid="AF0001_19776">1</xref></contrib><contrib contrib-type="author"><name><surname>Astuti</surname><given-names>Noemi</given-names></name><xref ref-type="aff" rid="AF0001_19776">1</xref></contrib><contrib contrib-type="author"><name><surname>Di Filippo</surname><given-names>Elisa</given-names></name><xref ref-type="aff" rid="AF0001_19776">1</xref></contrib><contrib contrib-type="author"><name><surname>Benatti</surname><given-names>Simone</given-names></name><xref ref-type="aff" rid="AF0001_19776">1</xref></contrib><contrib contrib-type="author"><name><surname>Valenti</surname><given-names>Daniela</given-names></name><xref ref-type="aff" rid="AF0001_19776">1</xref></contrib><contrib contrib-type="author"><name><surname>Callegaro</surname><given-names>Anna Paola</given-names></name><xref ref-type="aff" rid="AF0002_19776">2</xref></contrib><contrib contrib-type="author"><name><surname>Rizzi</surname><given-names>Marco</given-names></name><xref ref-type="aff" rid="AF0002_19776">2</xref></contrib></contrib-group><aff id="AF0001_19776"><label>1</label>Division of Infectious Diseases, AO Papa Giovanni XXIII BergamoBergamo, Italy</aff><aff id="AF0002_19776"><label>2</label>Laboratory of Virology and Microbiology, AO Papa Giovanni XXIII Bergamo, Bergamo, Italy</aff><pub-date pub-type="epub"><day>02</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>17</volume><issue>4Suppl 3</issue><elocation-id content-type="doi">19776</elocation-id><permissions><copyright-statement>&#x000a9; 2014 Maggiolo F et al; licensee International AIDS Society</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1_19776"><title>Introduction</title><p>The long-term effects of an intensified induction regimen are unknown. In this pilot, randomized, prospective study we evaluate the effect of a short-term four-drugs induction regimen in patients with high baseline viral load.</p></sec><sec id="st2_19776"><title>Methods</title><p>Naive patients with HIV-RNA&#x0003e;100.000 copies/ml receiving TDF+FTC+EFV+RAL (group ER) for 4 months and were then simplified to TDF+FTC+EFV. Two randomized control groups treated <italic>ab-initio</italic> with TDF+FTC+EFV (E) or TDF+FTC+RAL (R) were used.</p></sec><sec id="st3_19776"><title>Results</title><p>19 patients with a mean age of 38 years and mean baseline CD4 count of 334 (SD 216) cells/mcL and HIV-RNA of 5.47 log (SD 0.32) copies/mL were enrolled. No baseline significant difference was observed among groups. Early HIV-RNA reduction was significantly higher in ER compared to the other groups from week 1 to week 4 (P from 0.026 to 0.003) (<xref ref-type="fig" rid="F0001_19776">figure 1</xref>), thereafter HIV-RNA values were comparable among the groups. At week 96, all patients had an HIV-RNA &#x0003c; 50 copies/mL, however only patients in the ER group had in all cases an HIV-RNA level &#x0003c; 3 copies/mL with a statistically significant difference compared to E (60%; P=0.038) and R (50%; P=0.020). At 96 weeks, CD4 cell median counts were 765 cells/mcL for ER, 600 cells/mcL for E and 771 for R (P=0.16), however patients in the ER group presented a lower proport<bold>i</bold>on of activated CD4+CD38+HLADR+ cells (1.9% versus 3.9 and 3.8%) and CD8+CD38+HLADR+ cells (10.3% versus 16.8 and 16.5%) and a significantly better CD4/CD8 ratio (0.98 versus 0.53 and 0.61; P=0.03).</p></sec><sec id="st4_19776"><title>Conclusions</title><p>A four-drug regimen in naive patients with high pre-therapy viral load improves early virologic response. A quick drop of HIV-RNA seems to correlate with a sustained virologic response. Although limited in time (four months), the four-drug regimens correlates with an improved immunological response as measured by the CD4/CD8 ratio or the percentage of activated CD4+ and CD8+ cells. The reasons why this happens deserve further studies. This study highlights the importance of a personalised therapy especially in high risk patients.
</p></sec></abstract></article-meta></front><body><fig id="F0001_19776" position="float"><label>Figure 1</label><caption><p>HIV-RNA reduction among the three groups.</p></caption><graphic xlink:href="JIAS-17-19776-g001"/></fig></body><back><ref-list><title>Reference</title><ref id="CIT0001_19776"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Maggiolo</surname><given-names>F</given-names></name><name><surname>Masini</surname><given-names>G</given-names></name><name><surname>Astuti</surname><given-names>N</given-names></name><name><surname>Di Filippo</surname><given-names>E</given-names></name><name><surname>Benatti</surname><given-names>S</given-names></name><name><surname>Valenti</surname><given-names>D</given-names></name><etal/></person-group><article-title>Division of Infectious Diseases; Laboratory of Virology and Microbiology; AO Papa Giovanni XXIII Bergamo, Italy</article-title></element-citation></ref></ref-list></back></article>